First Trust Advisors
JANX icon

First Trust Advisors’s Janux Therapeutics JANX Stock Holding History

First Trust Advisors’s Portfolio JANX Stock Details JANX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-114,502
Closed -$3.09M – 2650
2025
Q1 		$3.09M Sell
114,502
-13,560
-11% -$511K ﹤0.01% 1575
2024
Q4 		$6.86M Buy
+128,062
New +$6.77M 0.01% 1207

Other funds holding JANX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

First Trust Advisors's JANX Position: Q2 2025 in Review

First Trust Advisors sold out of Janux Therapeutics (JANX) in Q2 2025, closing a stake of 114,502 shares — an estimated $3.09M sold.

First Trust Advisors first reported a position in JANX in Q4 2024 and held it in 2 quarters. The position peaked at $6.86M in Q4 2024. 174 funds tracked by Wall St. Rank hold JANX as of Q2 2025.

  • First Trust Advisors reported no remaining Janux Therapeutics position as of Q2 2025 after selling out during the quarter.
  • First Trust Advisors sold 114,502 Janux Therapeutics shares in Q2 2025, an estimated $3.09M.
  • First Trust Advisors first reported a position in Janux Therapeutics in Q4 2024 and held it in 2 quarters.
  • First Trust Advisors's Janux Therapeutics position peaked at $6.86M in Q4 2024.
  • 174 funds tracked by Wall St. Rank held Janux Therapeutics as of Q2 2025.

Based on First Trust Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.